CR20230262A - Inhibidor de integrina y usos de este - Google Patents

Inhibidor de integrina y usos de este

Info

Publication number
CR20230262A
CR20230262A CR20230262A CR20230262A CR20230262A CR 20230262 A CR20230262 A CR 20230262A CR 20230262 A CR20230262 A CR 20230262A CR 20230262 A CR20230262 A CR 20230262A CR 20230262 A CR20230262 A CR 20230262A
Authority
CR
Costa Rica
Prior art keywords
crystalline forms
methods
inhibitors
integrin inhibitor
integrin
Prior art date
Application number
CR20230262A
Other languages
English (en)
Inventor
Gao Qi
Jacob Cha
Katerina Leftheris
Jian Wan
Dalian Zhao
Original Assignee
Pliant Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pliant Therapeutics Inc filed Critical Pliant Therapeutics Inc
Publication of CR20230262A publication Critical patent/CR20230262A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/33—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of six-membered aromatic rings being part of condensed ring systems
    • C07C309/34—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of six-membered aromatic rings being part of condensed ring systems formed by two rings
    • C07C309/35—Naphthalene sulfonic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

En la presente descripción se proporcionan inhibidores de integrina, composiciones de estos, y métodos para su uso. También se describen formas cristalinas de sales de los inhibidores, junto con métodos para preparar las formas cristalinas. Se proporcionan datos de difracción de polvo de rayos X, análisis termogravimétrico, y datos de calorimetría diferencial de barrido de las formas cristalinas. Los inhibidores de integrina son útiles en el tratamiento de, entre otras, las enfermedades fibróticas
CR20230262A 2020-11-19 2021-11-19 Inhibidor de integrina y usos de este CR20230262A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063116042P 2020-11-19 2020-11-19
PCT/US2021/072510 WO2022109598A1 (en) 2020-11-19 2021-11-19 Integrin inhibitor and uses thereof

Publications (1)

Publication Number Publication Date
CR20230262A true CR20230262A (es) 2023-07-26

Family

ID=81709878

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20230262A CR20230262A (es) 2020-11-19 2021-11-19 Inhibidor de integrina y usos de este

Country Status (19)

Country Link
US (2) US12018025B2 (es)
EP (1) EP4247472A4 (es)
JP (1) JP2023550428A (es)
KR (1) KR20230121761A (es)
CN (1) CN116710169A (es)
AU (1) AU2021381516A1 (es)
CA (1) CA3173755A1 (es)
CL (1) CL2023001418A1 (es)
CO (1) CO2023006522A2 (es)
CR (1) CR20230262A (es)
CU (1) CU20230026A7 (es)
DO (1) DOP2023000101A (es)
EC (1) ECSP23045278A (es)
IL (1) IL302651A (es)
JO (1) JOP20230102A1 (es)
MX (1) MX2023005889A (es)
PE (1) PE20240114A1 (es)
TW (1) TW202235417A (es)
WO (1) WO2022109598A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE50554E1 (en) 2016-12-23 2025-08-26 Pliant Therapeutics, Inc. Amino acid compounds and methods of use
TWI841573B (zh) 2018-06-27 2024-05-11 美商普萊恩醫療公司 具有未分支連接子之胺基酸化合物及使用方法
US11419869B2 (en) 2019-04-08 2022-08-23 Pliant Therapeutics, Inc. Dosage forms and regimens for amino acid compounds
CN120091811A (zh) * 2022-07-09 2025-06-03 普利安特治疗公司 整合素抑制剂及其与其它药剂组合的用途
WO2024155965A2 (en) * 2023-01-21 2024-07-25 Pliant Therapeutics, Inc. Biomarkers for use in integrin inhibitor therapy
WO2025072206A1 (en) * 2023-09-25 2025-04-03 Pliant Therapeutics, Inc. Integrin inhibitors for treatment of primary sclerosing cholangitis
TW202535400A (zh) 2023-12-14 2025-09-16 美商普萊恩醫療公司 整合素抑制劑及其用途
WO2025217571A1 (en) * 2024-04-12 2025-10-16 Pliant Therapeutics, Inc. Fixed dose combinations of integrin inhibitor with ppar agonists

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013184572A1 (en) * 2012-06-04 2013-12-12 Pharmacyclics, Inc. Crystalline forms of a bruton's tyrosine kinase inhibitor
WO2015048819A1 (en) 2013-09-30 2015-04-02 The Regents Of The University Of California Anti-alphavbeta1 integrin compounds and methods
CA2981371A1 (en) 2015-03-10 2016-09-15 The Regents Of The University Of California Anti-alphavbeta1 integrin inhibitors and methods of use
CN109996541A (zh) 2016-09-07 2019-07-09 普利安特治疗公司 N-酰基氨基酸化合物及其使用方法
USRE50554E1 (en) 2016-12-23 2025-08-26 Pliant Therapeutics, Inc. Amino acid compounds and methods of use
SG11201907820SA (en) 2017-02-28 2019-09-27 Morphic Therapeutic Inc Inhibitors of (alpha-v)(beta-6) integrin
US11046685B2 (en) 2017-02-28 2021-06-29 Morphic Therapeutic, Inc. Inhibitors of (α-v)(β-6) integrin
LT3761980T (lt) 2018-03-07 2024-03-12 Pliant Therapeutics, Inc. Aminorūgščių junginiai ir jų panaudojimo būdai
TWI841573B (zh) 2018-06-27 2024-05-11 美商普萊恩醫療公司 具有未分支連接子之胺基酸化合物及使用方法
WO2020016704A1 (ja) * 2018-07-20 2020-01-23 株式会社半導体エネルギー研究所 撮像パネル、撮像装置
CA3109534A1 (en) 2018-08-29 2020-03-05 Morphic Therapeutic, Inc. Inhibiting .alpha.v .beta.6 integrin
EP3843727A4 (en) 2018-08-29 2022-08-17 Morphic Therapeutic, Inc. INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN
ES3027421T3 (en) 2018-08-29 2025-06-13 Morphic Therapeutic Inc Inhibitors of (alpha-v)(beta-6) integrin
TW202028179A (zh) 2018-10-08 2020-08-01 美商普萊恩醫療公司 胺基酸化合物及使用方法
EP3903316A1 (en) * 2018-12-28 2021-11-03 LunaPBC Community data aggregation, completion, correction, and use
EP3923857B8 (en) * 2019-02-15 2024-04-17 Clean Bite, LLC Oral hygiene appliance
US11419869B2 (en) * 2019-04-08 2022-08-23 Pliant Therapeutics, Inc. Dosage forms and regimens for amino acid compounds
EP4058481A1 (en) 2019-11-15 2022-09-21 Pliant Therapeutics, Inc. Compositions and methods for activation of integrins
CN115989235A (zh) 2020-05-07 2023-04-18 普利安特治疗公司 使用氨基酸化合物治疗呼吸系统疾病的方法
TWI838626B (zh) * 2020-06-03 2024-04-11 美商基利科學股份有限公司 Lpa受體拮抗劑及其用途
WO2022087224A1 (en) * 2020-10-21 2022-04-28 Cohbar, Inc. Method of treating fibrosis with a combination therapy
CA3173787A1 (en) 2021-04-30 2022-11-03 Scott Turner Expanded dosage regimens for integrin inhibitors
US20240350494A1 (en) 2021-09-03 2024-10-24 Pliant Therapeutics, Inc. Therapeutic modulation of integrins
EP4416147A1 (en) 2021-10-14 2024-08-21 Pliant Therapeutics, Inc. Integrin inhibitors and uses thereof in combination with other agents
WO2023225119A1 (en) 2022-05-18 2023-11-23 Pliant Therapeutics, Inc. Stabilization of integrin inhibitors

Also Published As

Publication number Publication date
PE20240114A1 (es) 2024-01-22
CU20230026A7 (es) 2024-01-10
ECSP23045278A (es) 2023-07-31
EP4247472A1 (en) 2023-09-27
US12018025B2 (en) 2024-06-25
US20220177468A1 (en) 2022-06-09
US20240391914A1 (en) 2024-11-28
AU2021381516A9 (en) 2024-10-24
CO2023006522A2 (es) 2023-06-09
CN116710169A (zh) 2023-09-05
AU2021381516A1 (en) 2023-06-22
JP2023550428A (ja) 2023-12-01
EP4247472A4 (en) 2024-10-09
CL2023001418A1 (es) 2023-10-30
IL302651A (en) 2023-07-01
DOP2023000101A (es) 2023-09-29
TW202235417A (zh) 2022-09-16
MX2023005889A (es) 2023-06-06
KR20230121761A (ko) 2023-08-21
WO2022109598A1 (en) 2022-05-27
CA3173755A1 (en) 2022-05-27
JOP20230102A1 (ar) 2023-05-08

Similar Documents

Publication Publication Date Title
MX2023005889A (es) Inhibidor de integrina y usos de este.
CR20200503A (es) Inhibidores de cinasa dependientes de ciclina
PH12022551661A1 (en) Mek inhibitors and therapeutic uses thereof
JOP20210001A1 (ar) مشتقات 3-(5- هيدروكسي -1- أوكسو أيزو إندولين -2- يل) بيبريدين -2، 6- دايون واستخدامها لمعالجة أمراض مرتبطة ببروتين ذات أصبع الزنك من عائلة (ikaros 2 (ikzf2
PH12021552482A1 (en) Compounds targeting prmt5
PH12019500329A1 (en) Pyridopyrimdinone cdk2/4/6 inhibitors
PH12021553233A1 (en) Imidazopyrimidines as eed inhibitors and the use thereof
TN2010000049A1 (en) Derivatives of n-(arylamino) sulfonamides includig polymorphs as inhibitors of mek as well as compositions, methods of use and methods for preparing the same
MX2020010437A (es) Inhibidores de axl cinasa y uso de los mismos.
EP4248988A3 (en) Alkenyl substituted 2,5-piperazinediones and their use in compositions for delivering an agent to a subject or cell
MD4820B1 (ro) Compuşi dihidroizochinolinonici substituiţi
TN2016000511A1 (en) 1, 3, 4-thiadiazole compounds and their use in treating cancer
EA201992320A1 (ru) Пиперидины в качестве ковалентных ингибиторов менина
MY158648A (en) Compositions for modulating a kinase cascade and methods of use thereof
EP4480483A3 (en) Solid state forms of belumosudil and belumosudil salts
MX2024010863A (es) Formas solidas, sales y procesos de preparacion de un inhibidor de cinasas dependientes de ciclina 2 (cdk2).
MX389800B (es) Piridinas sustituidas con heterociclilsulfonilo y su uso en el tratamiento del cancer
JOP20210072A1 (ar) ملح جديد لمثبط bcl-2، صورة بلورية ذات صلة، طريقة تحضيره وتركيبات صيدلية تحتوي عليه
MX2024005429A (es) Inhibidores de las fosfatidilinositol 3-cinasas-alfa (pi3k-alfa) y metodos para su produccion y uso.
GEP20125433B (en) α CRYSTALLINE FORM OF THE ARGININE SALT OF PERINDOPRIL, PROCESS FOR PREPARING IT, AND PHARMACEUTICAL COMPOSITIONS COMPRISING IT
GEAP202415849A (en) Crystalline salt forms of kinase inhibitor
WO2019195641A3 (en) 1,3,4-oxadiazoles as inhibitors of rho/mrtf/srf-mediated gene transcription and methods for use of the same
MX2025001201A (es) Sales y cristales novedosos
MX2020008273A (es) Inhibidores de la cinasa del complejo de activacion transcripcional notch ("nack") y metodos para el uso de los mismos.
RU2021124795A (ru) Твердые формы ингибитора ttk